安必平(688393) - 2025 Q4 - 年度业绩预告

Financial Performance Forecast - The company expects a net loss attributable to shareholders of between -52 million and -42 million yuan for the year 2025, a decrease of 73.29 million to 63.29 million yuan compared to the previous year, representing a year-on-year decline of 344.23% to 297.26%[3] - The anticipated net profit attributable to shareholders, after deducting non-recurring gains and losses, is projected to be between -72 million and -62 million yuan, a decrease of 86.25 million to 76.25 million yuan compared to the previous year, reflecting a year-on-year decline of 605.13% to 534.97%[3] - The company's total profit for the previous year was 9.4344 million yuan, with a net profit attributable to shareholders of 21.2913 million yuan, and a net profit after deducting non-recurring gains and losses of 14.2538 million yuan[5] Revenue and Profitability Challenges - The decline in revenue is primarily due to the implementation of national centralized procurement policies, which significantly reduced the selling price of the company's HPV product line, leading to a revenue decrease of approximately 46.5 million yuan[8] - The gross profit margin for the HPV product line also faced pressure, with a year-on-year decrease of approximately 46 million yuan[8] Business Strategy and Investment - The company is actively optimizing its business structure by focusing on core business revenue expansion and reducing the scale of agency product business[8] - To enhance long-term competitive advantage, the company is increasing its investment in product research and development, particularly in the fields of pathological intelligence and tumor companion diagnostics, despite a rise in operating costs[8] Non-Operating Income and Audit Information - Non-operating gains and losses have increased due to higher investment income from associated companies[9] - The financial data provided in the performance forecast has not been audited by a registered accountant and is subject to final audit results[10] - Investors are advised to pay attention to investment risks as the forecast data is preliminary and the accurate financial data will be disclosed in the audited annual report for 2025[12]